Compare · ICCC vs QDEL
ICCC vs QDEL
Side-by-side comparison of ImmuCell Corporation (ICCC) and QuidelOrtho Corporation (QDEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCC and QDEL operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- QDEL is the larger of the two at $789.1M, about 10.4x ICCC ($75.6M).
- Over the past year, ICCC is up 52.5% and QDEL is down 60.0% - ICCC leads by 112.6 points.
- ICCC has been more active in the news (18 items in the past 4 weeks vs 9 for QDEL).
- QDEL has more recent analyst coverage (18 ratings vs 0 for ICCC).
- Company
- ImmuCell Corporation
- QuidelOrtho Corporation
- Price
- $8.39+8.96%
- $11.60+3.25%
- Market cap
- $75.6M
- $789.1M
- 1M return
- +31.50%
- -27.67%
- 1Y return
- +52.55%
- -60.03%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1987
- News (4w)
- 18
- 9
- Recent ratings
- 0
- 18
ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Latest ICCC
- SEC Form DEF 14A filed by ImmuCell Corporation
- SEC Form 3 filed by new insider Dimarco Anthony
- SEC Form 3 filed by new insider Guillemette Gilles
- SEC Form 4 filed by Turner Kathy V
- SEC Form 4 filed by Tomsche David Scott
- SEC Form 4 filed by Basse Gloria F
- SEC Form 4 filed by Wainman Paul R
- SEC Form PRE 14A filed by ImmuCell Corporation
- SEC Form 4 filed by Gathagan Bryan K.
- SEC Form 4 filed by Wainman Paul R
Latest QDEL
- Chief Operations Officer Mclellan Philip D. was granted 3,238 shares and covered exercise/tax liability with 1,162 shares, increasing direct ownership by 11% to 21,250 units (SEC Form 4) (for tax liability)
- EVP Global Port. Mgmt & Mkting Hanson Bryan Michael was granted 3,508 shares and covered exercise/tax liability with 1,269 shares, increasing direct ownership by 249% to 3,139 units (SEC Form 4) to cover taxes
- Understanding and Addressing Syphilis Trends - and What's Being Missed
- SEC Form 4 filed by Sisitsky Nathaniel
- TTP Group Announces the Sale of LEX Diagnostics
- QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics
- QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
- Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation
- SEC Form 3 filed by new insider Sisitsky Nathaniel